RxDoctor Payments Data

Edward Kerwin, MD

Allergy · Medford, ORNPI 1568465847

Payments from drug & device makers

$6,760,329in general payments, 2019–2025

Across 610 payments — averaging $11,083 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Romark Laboratories, LC$1.1M
  • Amphastar Pharmaceuticals, Inc.$943K
  • Teva Pharmaceuticals USA, Inc.$695K
  • Cipla USA Inc.$523K
  • Hikma Pharmaceuticals USA$430K
  • AstraZeneca$376K
  • plus $2.7M from 25 others
$198,494in research payments, 2019–2025

Across 96 payments — averaging $2067.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ichnos Glenmark Innovation Inc$144K
  • Glenmark Pharmaceuticals Inc., USA$51K
  • Chiesi USA, Inc.$3K
  • Sanofi US Services Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$60

What the payments were for

  • Consulting fees$30,78946%
  • Speaking & faculty fees$19,51329%
  • Grants$4501%
  • Travel & lodging$12,29219%
  • Food & beverage$3,1835%
  • Education$90%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$160,359
Medicare patients
283
Services billed
10,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol31$21,155
Fluticasone-SalmeterolFluticasone Propion/Salmeterol65$16,655
Albuterol Sulfate HfaAlbuterol Sulfate64$3,702
Fluticasone Propionate60$984
Montelukast Sodium49$947
Triamcinolone Acetonide28$510
Prednisone91$311
Doxycycline Hyclate13$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$359,186$21,15531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other allergy in Medford

Where these figures come from

Is this you, or does something look wrong? →